Strike two for overheated South Korean biotech
Pexa-Vec fails earlier than expected, dealing exuberant South Korean biotech investors and the oncolytic virus field another blow.
Go or no go? Abbvie, Roche and Kala await key decisions
One of the biggest drugs of the year, Abbvie’s Jak inhibitor upadacitinib, could get the nod in August.
Opdivo’s lung cancer latest: one fail, one shrug
Bristol-Myers Squibb’s byzantine Checkmate-227 study yields one flop and one technical success that, in reality, counts for nothing.
Abbvie hopes to turn around the fortunes of Sting
Continued interest in the Sting pathway might come as a surprise, though secrecy suggests that asset prices are failing.
Through Gilead, Galapagos secures an independent future
For $5bn up front Gilead has effectively gained access to the Belgian company’s pipeline, in a deal that will tie the US biotech to Galapagos for many years to come.
Back to business for biotech flotations
After a quiet first quarter demand for new issues has returned to levels seen in 2018, itself a record year for IPOs of young drug developers.
Twilight of the stem cell transplant adjuncts?
The ripples of Molmed’s pivotal study failure could stretch beyond the company’s Zalmoxis product.
Big hitters eye Sjögren’s syndrome white space
Orencia’s late-stage failure in Sjögren’s has dashed hopes of a therapy soon, but the mid-stage pipeline is crowded, with Novartis, Glaxosmithkline and Galapagos all…
Upcoming events – Crucial data approach on zanubrutinib and filgotinib
Beigene seeks very good data in Waldenström's macroglobulinaemia, while Galapagos aims to extend filgotinib's reach.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.